Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.38 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 known ✓ | Q99500 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KDM5C | P41229 | 2/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8650017 | 1.00 | LMNA (0.47) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| Hydrochloric Acid SCHEMBL6306661 | 1.00 | LMNA (0.47) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| Hydrochloric Acid SCHEMBL4199437 | 0.97 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| SCHEMBL12491912 | 0.97 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| SCHEMBL5035377 | 0.97 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| SCHEMBL17433002 | 0.97 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| SCHEMBL20415450 | 0.97 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| SCHEMBL162041 | 0.97 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| SCHEMBL109879 | 0.94 | LMNA (0.53) | LMNAEGLN1ALKBH5SUCNR1ECE1 | |
| SCHEMBL28473579 | 0.90 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963761-B2 | Mediation of in vivo analyte signal degradation | SENSEONICS, INCORPORATED (US) | 2024-04-23 | — | — | US | claimed |
| US-11744248-B2 | Disinfectant composition for control of clostridium difficile spore | ENVIRO SPECIALTY CHEMICALS INC. (US) | 2023-09-05 | — | — | US | claimed |
| EP-3847889-A1 | BIOCIDAL COMPOSITIONS COMPRISING IRON CHELATORS | Arch Chemicals, Inc. (US) | 2021-07-14 | — | — | EP | claimed |
| US-20200359943-A1 | MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION | SENSEONICS, INCORPORATED (US) | 2020-11-19 | — | — | US | claimed |
| US-20200170249-A1 | Biocidal Compositions Comprising Iron Chelators | ARCH CHEMICALS, INC. | 2020-06-04 | — | — | US | claimed |
| WO-2019040374-A1 | DISINFECTANT COMPOSITION FOR CONTROL OF CLOSTRIDIUM DIFFICILE SPORES | ENVIRO SPECIALTY CHEMICALS INC. (US) | 2019-02-28 | — | — | WO | claimed |
| US-20190053494-A1 | DISINFECTANT COMPOSITION FOR CONTROL OF CLOSTRIDIUM DIFFICILE SPORE | ENVIRO SPECIALTY CHEMICALS, INC. | 2019-02-21 | — | — | US | claimed |
| US-20180318402-A1 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS | PROTHERA LLC (US) | 2018-11-08 | — | — | US | claimed |
| US-9987337-B2 | Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions | PROTHERA, INC. (US) | 2018-06-05 | — | — | US | claimed |
| US-9737591-B2 | Compositions and methods comprising serratia peptidase for inhibition of bacterial vaginosis, bacterial vaginitis or fungal vaginitis | PROTHERA, INC. (US) | 2017-08-22 | — | — | US | claimed |
| EP-1781312-A2 | FORMULATIONS AND METHODS FOR MODULATING SATIETY | Rosenberg, Mark (US) | 2007-05-09 | — | — | EP | claimed |
| EP-1017427-B1 | USE OF A COMPOSITION COMPRISING A CHELATING AGENT AND AN ANTIMICROBIAL COMPOUND FOR THE TREATMENT OF BIOFILMS | UNIV TEXAS (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2006023976-A2 | FORMULATIONS AND METHODS FOR MODULATING SATIETY | ROSENBERG MARK (US) | 2006-03-02 | — | — | WO | claimed |
| US-20050143286-A1 | such as lactoferrin, conalbumin; combinations with antibiotics, microbiocides for e.g. disinfecting, preserving food, treating infections; also chelating agents such as ,19,30-trioxa-1,4,10,13,16,22,27,33-octaazabicyclo(11,11,11)pentatriacontane hexahydrobromide | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-06-30 | — | — | US | claimed |
| US-6852495-B2 | Process of extracting nucleic acid and process of simultaneously carrying out extraction and purification of nucleic acid | SHIMADZU CORPORATION (JP) | 2005-02-08 | — | — | US | claimed |
| EP-1499341-A2 | METHODS OF INHIBITING AND TREATING BACTERIAL BIOFILMS BY METAL CHELATORS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-01-26 | — | — | EP | claimed |
| US-20030229222-A1 | Process of extracting nucleic acid and process of simultaneously carrying out extraction and purification of nucleic acid | SHIMADZU CORPORATION (JP) | 2003-12-11 | — | — | US | claimed |
| WO-2003088914-A2 | METHODS OF INHIBITING AND TREATING BACTERIAL BIOFILMS BY METAL CHELATORS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2003-10-30 | — | — | WO | claimed |
| US-6267979-B1 | PROVIDINY AQUEOUS SYSTEM FORMULATION COMPRISING CHELATING AGENT, AN ANTIMICROBIAL TO CONTROL GROWTH OF MICROORGANISMS | WAKE FOREST UNIVERSITY | 2001-07-31 | — | — | US | claimed |
| EP-0716149-A1 | METHOD OF DETERMINING SODIUM ION | KYOWA MEDEX CO., LTD. (JP) | 1996-06-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744248-B2 | Disinfectant composition for control of clostridium difficile spore | EPCAM, DSTN, DSG1 | HDAC3 349/4885HDAC1 660/4885HDAC2 1026/4885 |
| US-20190053494-A1 | DISINFECTANT COMPOSITION FOR CONTROL OF CLOSTRIDIUM DIFFICILE SPORE | EPCAM, DSTN, DSG1 | HDAC3 349/4885HDAC1 660/4885HDAC2 1026/4885 |
| US-20200170249-A1 | Biocidal Compositions Comprising Iron Chelators | SLC40A1, TFRC, SLC39A14 | HDAC3 2695/4885HDAC1 1287/4885HDAC2 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.